Bracco’s “The Beauty of Imaging” The multimedia installation explaining the importance of diagnostic imaging is now on display at STEP, to relate the future of radiology and precision medicine

Bracco dans le monde le Groupe Bracco intervient dans le monde entier

Bracco joins the UN Global Compact The UN Global Compact is a call to companies everywhere to align their operations and strategies with ten universally accepted principles in the areas of human rights, labour, environment and anti-corruption.

Efficacy and Safety of Gadopiclenol The results of the multicenter, multinational PICTURE clinical trial demonstrate that 0.05 mmol/kg gadopiclenol provides similar morphologic information about CNS lesions and greater contrast enhancement compared with 0.1 mmol/kg gadobutrol.

Whistleblowing Procedures and guidelines for Whistleblowing

Bracco’s VUEWAY™ (gadopiclenol) injection now in hospitals Preeminent Hospitals and Medical Practices Nationwide Lead in Patient Care with First Use of Bracco’s VUEWAY™ (gadopiclenol) solution for injection for MRI.

Bracco announces the birth of Bracco Japan Ltd Bracco will acquire all shares of Bracco-Eisai held by Eisai and change its name from Bracco-Eisai to Bracco Japan, Ltd.  as of April 1, 2023.

Bracco è Marchio Storico di Interesse Nazionale L’azienda, nata nel 1927 e oggi leader globale nella diagnostica per immagini, entra a far parte dell’esclusivo gruppo di imprese storiche che rappresentano la punta di diamante del Made in Italy.

ACR Classification of Gadopiclenol as Group II Agent Discover why ACR designated Gadopiclenol as a Group II agent and what this means for patient safety and diagnostic accuracy in MRI imaging.

Our New Iodine Recollection Pilot and Re.Viva Re.Viva works to capture and redeploy used substances in the positive momentum of the circular economy: the Bracco Iodine Recollection Pilot